Related Experiment Video
Updated: Feb 28, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study
Karla Claudio-Campos1, Aurora Labastida2, Alga Ramos3
1Department of Pharmacology and Toxicology, School of Medicine, University of Puerto RicoSan Juan, PR, United States.
Insights
New genetic variants, including CYP2C9 rs2860905, improve warfarin dose prediction in Caribbean Hispanics. This study identifies key genetic factors for personalized warfarin therapy in diverse populations.
Area of Science:
- Pharmacogenomics
- Human Genetics
- Cardiovascular Medicine
Background:
- Existing warfarin dosing algorithms explain ~50% of dose variance, with limited performance in non-Caucasian populations due to overlooked ethno-specific variants.
- Warfarin pharmacogenetics is crucial for personalized medicine, but knowledge gaps exist for diverse ethnic groups.
Purpose of the Study:
- To identify genetic polymorphisms influencing warfarin dose variability in Caribbean Hispanics from Puerto Rico.
- To characterize the genomic structure and admixture patterns of the study cohort.
Main Methods:
- Next-Generation Sequencing of CYP2C9 and VKORC1, and genotyping via DMET® Plus Assay.
- Case-control association analysis using the Extreme Discordant Phenotype approach.
- Genomic structure and admixture analysis.
Main Results:
- The CYP2C9 variant rs2860905 showed a stronger association with warfarin sensitivity than CYP2C9*2 and CYP2C9*3.
- Polymorphisms in CES2 and ABCB1 were linked to warfarin resistance.
- A regression model incorporating rs2860905, other genetic factors, and non-genetic factors improved warfarin dose prediction (R² = 0.63).
Conclusions:
- Novel genetic variants, particularly CYP2C9 rs2860905, enhance the predictability of warfarin dosing in Caribbean Hispanics.
- The Puerto Rican cohort exhibits a tri-hybrid admixture pattern with significant Native American ancestry.
- Findings highlight the need for population-specific genetic data in pharmacogenomic studies for warfarin therapy.
Abstract:
Existing algorithms account for ~50% of observed variance in warfarin dose requirements after including common polymorphisms. However, they do not perform as well in populations other than Caucasians, in part because some ethno-specific genetic variants are overlooked. The objective of the present study was to identify genetic polymorphisms that can explain variability in warfarin dose requirements among Caribbean Hispanics of Puerto Rico. Next-Generation Sequencing of candidate genes CYP2C9 and VKORC1 and genotyping by DMET® Plus Assay of cardiovascular patients were performed. We also aimed at characterizing the genomic structure and admixture pattern of this study cohort. Our study used the Extreme Discordant Phenotype approach to perform a case-control association analysis. The CYP2C9 variant rs2860905, which was found in all the major haplotypes occurring in the Puerto Rican population, showed stronger association with warfarin sensitivity (<4 mg/day) than common variants CYP2C9*2 and CYP2C9*3. Although, CYP2C9*2 and CYP2C9*3 are separately contained within two of the haplotypes, 10 subjects with the sensitive phenotype were carriers of only the CYP2C9 rs2860905 variant. Other polymorphisms in CES2 and ABCB1 were found to be associated with warfarin resistance. Incorporation of rs2860905 in a regression model (R2 = 0.63, MSE = 0.37) that also includes additional genetics (i.e., VKORC1-1639 G>A; CYP2C9 rs1856908; ABCB1 c.IVS9-44A>G/ rs10276036; CES2 c.269-965A>G/ rs4783745) and non-genetic factors (i.e., hypertension, diabetes and age) showed better prediction of warfarin dose requirements than CYP2C9*2 and CYP2C9*3 combined (partial R2 = 0.132 vs. 0.023 and 0.007, respectively, p < 0.001). The genetic background of Puerto Ricans in the study cohort showed a tri-hybrid admixture pattern, with a slightly higher than expected contribution of Native American ancestry (25%). The genomic diversity of Puerto Ricans is highlighted by the presence of four different major haplotype blocks in the CYP2C9 locus. Although, our findings need further replication, this study contributes to the field by identifying novel genetic variants that increase predictability of stable warfarin dosing among Caribbean Hispanics.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pharmacogenomics: Identification of New Drug Targets
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Principles of Pharmacogenetics: Types of Genetic Variants

